MAPT and tauopathy: In the current study, we evaluated a disconnect between the ability for a chimeric intrabody fused to ubiquitin harboring a mutation prone for lysosome-mediate degradation to reduce tau protein levels in primary neuronal cultures/HEK293t cells and its inability to reduce tauopathy in vivo in aged P301S-tg mice.